Xeris Biopharma Holdings (XERS) Free Cash Flow (2020 - 2026)

Xeris Biopharma Holdings has reported Free Cash Flow for 7 years, with the latest figure at $9.9 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 198.39% year-over-year to $9.9 million; the trailing twelve-month figure through Mar 2026 stood at $48.5 million (up 281.69% YoY), and the FY2025 full-year result was $28.6 million, up 177.41% from the prior year.
• Free Cash Flow for Q1 2026 stood at $9.9 million, down from $20.0 million in the prior quarter.
• The five-year high for Free Cash Flow was $20.0 million in Q4 2025, with the low at -$48.4 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$8.7 million across 5 years, with a median of -$10.3 million in 2024.
• Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 102.07% — and 2025, when it soared 914.84%.
• Xeris Biopharma Holdings' Free Cash Flow stood at -$16.1 million in 2022, then jumped by 146.35% to $7.5 million in 2023, then slumped by 73.56% to $2.0 million in 2024, then soared by 914.84% to $20.0 million in 2025, then slumped by 50.76% to $9.9 million in 2026.
• The last three Free Cash Flow figures came in at $9.9 million (Q1 2026), $20.0 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.